Application of hyperoside in preparation of medicine for preventing and treating brain aging
Through hypericin targeting to improve the AQP4 polarity of astrocytes, the problem of lack of treatment methods for astrocytes in the prior art has been solved, and the effect of delaying brain aging is achieved, and a new anti-brain aging drug is used to solve the problem of lack of treatment methods for astrocytes in the prior art. The development provides a theoretical basis.
Patent Information
- Application Number
- CN202411675749.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-22
- Publication Date
- 2024-12-20
AI Technical Summary
The existing methods for preventing and treating brain aging are relatively scarce for specific treatment methods for astrocytes, lack effective interventions to directly improve their functions, and traditional Chinese medicine treatment is difficult to finely regulate the cellular level, resulting in insufficient clarity in the efficacy and mechanism.
Hyperaminoglycoside is used as a natural flavonoid compound to improve the polarity of aquaporin 4 (AQP4) and delay the aging of astrocytes, providing a new therapeutic approach for preventing and treating brain aging.
Hypericin reduces astrocyte senescence and delays brain aging by inhibiting autophagy mediated by the AMPK-ULK1 signaling pathway, providing a new treatment for astrocyte senescence and developing novel anti-anti-type anti-anti- Brain aging drugs provide a theoretical basis.
Smart Images

Figure CN119157893A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to the application of hyperoside in preparing drugs for preventing and treating brain aging. Background Art
[0002] The brain is an organ that is susceptible to aging, and brain aging further increases the risk of neurodegenerative diseases in the elderly. Glial cells, especially astrocytes, are the main type of senescent cells in the brain. The use of pharmacological or genetic methods to promote the clearance of aging glial cells can improve the cognitive function of aged mice and extend the overall life expectancy to a certain extent. It can be seen that targeted reduction of glial cell aging is a key way to delay brain aging. Astrocytes, as the most abundant type of glial cells in the central nervous system, not only provide structural support, but also participate in regulating various physiological processes such as water and electrolyte balance, energy metabolism, neurogenesis and transmitter transmission. With the increase of age, the function of astrocytes gradually declines, and their aging is closely related to various neurodegenerative diseases, such as Alzheimer's disease (AD) and other forms of brain aging. At present, both traditional Chinese and Western medicine have carried out relevant research, trying to reduce the aging of astrocytes through different drugs and methods. However, these methods have certain limitations in practical applications.
[0003] Western medicine methods for preventing and treating brain aging mainly include the use of drugs to regulate neurotransmitters, antioxidants, etc. Although these drugs can improve the function of neurons to a certain extent, their effects are often limited and may be accompanied by side effects. In addition, specific treatments for astrocytes are relatively scarce, and there is a lack of effective intervention measures to directly improve their functions. Traditional Chinese medicine mainly uses traditional Chinese medicine for treatment, and dasatinib and quercetin are believed to have certain anti-aging effects. Although these research results are exciting, there are still studies reporting that long-term use of anti-aging drugs has side effects and limitations such as thrombocytopenia and neutrophil reduction and tissue atrophy. However, there are relatively few studies on traditional Chinese medicine for delaying astrocyte aging, and the uncertainty of the treatment effect limits its clinical application. More importantly, existing traditional Chinese medicine treatments are often difficult to fine-tune at the cellular level, resulting in unclear efficacy and mechanisms.
[0004] In view of the defects of the above-mentioned prior art, the present invention proposes the use of hyperoside in reducing astrocyte aging and preventing and treating brain aging. Hyperoside is a natural flavonoid compound, which has been widely reported to reduce the load of amyloid β protein, improve cognitive damage and play a neuroprotective role in AD models, but its specific mechanism of action is still unclear. In addition, hyperoside reduces retinal photoreceptor cell aging and D-galactose-induced kidney aging and damage by inhibiting autophagy mediated by the AMPK-ULK1 signaling pathway. This lays a solid foundation for hyperoside to reduce astrocyte aging and delay brain aging. Summary of the invention
[0005] The inventors have discovered that hyperoside can be used to delay brain aging and prevent and treat related nervous system diseases.
[0006] The present invention provides the use of hyperoside in preparing a medicine for preventing and treating brain aging.
[0007] The dosage forms of drugs for preventing and treating brain aging are capsules, tablets, oral preparations, microcapsule preparations, injections, suppositories, sprays or ointments.
[0008] Pharmaceutically acceptable derivatives of hyperoside include solvates and salts, particularly acid addition salts such as hydrobromide.
[0009] The patient to be treated may suffer from a brain senescence disorder.
[0010] Patients to be treated usually take it in the following form: Oral supplements: These come in capsules, tablets, or liquid extracts.
[0011] Herbal Tea: A tea can be prepared by steeping Hypericum leaves or flowers.
[0012] Regarding dosage, the generally recommended dosage range is: Oral supplements: 100-500 mg per day. The specific dosage should be adjusted according to individual circumstances and product instructions.
[0013] Experiments have shown that hyperoside delays the aging of astrocytes by targeting and improving the polarity of aquaporin-4 (AQP4), providing a new therapeutic approach for delaying brain aging and preventing and treating related neurological diseases. This discovery not only expands the research on the pharmacological effects of hyperoside, but also provides a theoretical basis for the development of new anti-brain aging drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1A It is a flow chart of validating the aging astrocyte model provided by the present invention; Figure 1BIt is a scatter plot of senescent astrocytes analyzed by flow cytometry provided by the present invention; Figure 1C is a bar graph of astrocyte purity in statistical flow cytometry provided by the present invention; Figure 1D It is a bar graph of the proportion of senescent astrocytes in the statistical flow cytometry provided by the present invention; Figure 1E It is the immunofluorescence staining diagram of young and aged astrocytes provided by the present invention; Figure 1F is a bar graph of the proportion of senescent astrocytes in the statistical immunofluorescence experiment provided by the present invention; Figure 1G This is a Western blotting data diagram of young and aged astrocytes provided by the present invention; Figure 1H It is a bar graph of aging indicators in the statistical Western blotting experiment provided by the present invention; Figure 2A This is a cell viability diagram of senescent astrocytes treated with hyperoside provided by the present invention for 48 hours; Figure 2B This is a cell viability diagram of senescent astrocytes treated with hyperoside provided by the present invention for 72 hours; Figure 3A This is a flow chart of an experiment for preliminary screening of the optimal concentration of hyperoside provided by the present invention; Figure 3B It is a Western blotting data diagram of detecting aging indicators and the like after treating aging astrocytes with different concentrations of hyperoside provided by the present invention; Figure 4A This is an experimental process map for verifying the pharmacological effect of hyperoside in delaying astrocyte aging provided by the present invention; Figure 4B It is a Western blotting data diagram of detecting aging indicators and the like after treating aging astrocytes with hyperoside, positive control and negative control provided by the present invention; Figure 4C The present invention provides an immunofluorescence image of detecting β-gal after treating senescent astrocytes with hyperoside and a negative control. DETAILED DESCRIPTION
[0015] The invention is illustrated by the following examples.
[0016] The structure of hyperoside: O || HO-C6H4-CO-C6H3(OH)-C=O | C6H4 The specific technical solutions of the present invention are as follows: 1. Establishment of an in vitro senescent astrocyte model Primary astrocytes were isolated and prepared from newborn mice 1-2 days old. The brain tissue of the newborn mice was removed and the meninges and blood vessels were removed under a stereomicroscope. The tissue was minced with scissors and digested with 0.05% trypsin (Gibco, catalog number: #25-200-056) for 5-10 min. The tissue homogenate was filtered through a 70 μm filter, and the filtered cell suspension was centrifuged and resuspended in DMEM (Gibco, catalog number: #11960) culture medium containing penicillin / streptomycin (Gibco, catalog number: #15-140-122) and 10% fetal bovine serum (Gibco, catalog number: #1861242), and then seeded in a 10 cm culture dish and incubated in an incubator at 37°C and 5% CO2. Using the principle of cell replicative senescence, primary astrocytes were continuously subcultured for at least 40 days. Flow cytometry was used to detect the labeling of SA-β-gal (Cell Signaling Technology, Catalog No.: #9860) substrate C12FDG (GlpBio, Catalog No.: #GC43021) and astrocyte marker ACSA-2 (1:50, Miltenyi, Catalog No.: #130-123-284) and then immunofluorescence staining and Western blotting were used to detect aging-related markers such as p16, p53 and Lamin B1 to verify the in vitro aging astrocyte model (e.g. Figure 1A , 1B , 1C, 1D, 1E, 1F, 1G, and 1H).
[0017] 2. Cell processing Aged astrocytes were treated with hyperoside (MCE, Catalog No.: #HY-N0452) at a concentration gradient of 0, 0.1, 1, and 10 μM for 48 and 72 hours, respectively, to evaluate the cell viability of aged astrocytes and to determine the optimal concentration and duration of action of hyperoside (e.g. Figure 2A , 2B as shown).
[0018] 3. Immunofluorescence After fixation with 4% PFA at room temperature for 15 min, the cell slides were blocked and permeabilized with blocking solution containing 0.3% Triton X-100 and 5% fetal bovine serum at room temperature for 1 hour. The samples were incubated with primary antibodies at 4°C overnight. The next day, after washing with PBS three times, fluorescent secondary antibodies (1:1000 dilution) were incubated at room temperature for 2 hours. After washing with PBS, 4', 6-diamidino2-phenylindole (DAPI, 1 μg / mL) was incubated for 5-8 min to stain the nuclei. The meninges were carefully flattened and attached to the slides. All samples were covered with coverslips and placed in the dark and images were acquired as soon as possible using a fluorescence microscope (Leica, DM4000B, Germany) or a confocal microscope (Zeiss LSM710, Germany).
[0019] 4. Western blotting Cell samples were lysed with RIPA lysis buffer (Beyotime biotechnology, catalog number: #P0013B) containing protease inhibitors (Beyotime biotechnology, catalog number: #st506) and phosphatase inhibitors (Roche, catalog number: #04906845001). After ultrasonic grinding, the samples were incubated on ice for 20 min to fully lyse the samples. The lysate solution was centrifuged at 13000 rpm for 20 min at 4°C, and the supernatant was collected. All protein supernatants were subjected to BCA protein concentration determination (Beyotime biotechnology, catalog number: #P0009). The protein supernatant was mixed with 6× loading buffer, boiled at 95°C for 10 min in a metal bath, and stored at -20°C for later use after aliquoting. 20-30 μg of protein sample was added to the sample wells of 8-15% polyacrylamide gel, and protein markers were added to indicate the band positions. After appropriate electrophoresis time, the samples were transferred to 0.20 μm PVDF membranes. After transfer, the bands were blocked in 5% skim milk in TBST at room temperature for 1 hour. The bands were then incubated with primary antibodies overnight at 4°C on a shaker. The next day, the membrane was washed 3 times with TBST for 10 min each time, and then incubated with HRP-conjugated secondary antibodies at room temperature for 1 hour. All bands were washed 5 times with TBST for 10 min each time, and then developed using an imaging system (ImageQuant™ LAS 4000 mini, version 1.2). The grayscale value of each band was analyzed using Image J.
[0020] 1. Experimental Materials 1.1 Cell culture: Culture astrocytes under appropriate culture conditions until they reach the logarithmic growth phase.
[0021] 1.2 Experimental reagents: Purchase 99.5% pure hyperoside for treating senescent cells. Use appropriate cell culture medium and add appropriate amount of fetal bovine serum (FBS) and antibiotics. Use primary antibodies p16 (Proteintech, Catalog No.: #28416-1-AP), p53 (Proteintech, Catalog No.: #60283-2-Ig) and Lamin B1 (Abcam, Catalog No.: #ab16048) and secondary antibodies according to the dilution ratio specified.
[0022] 2. Experimental Content 2.1 Hyperoside treatment: Different concentrations of hyperoside (e.g., 0, 0.1, 1, and 10 µM) were added to the established senescent astrocyte model and treated for 48 and 72 hours.
[0023] 2.2 Assessment of cell viability: The CCK-8 method was used to determine the cell activity and evaluate the effect of hyperoside on cell survival.
[0024] 2.3 Detection of aging markers: The expression levels of relevant aging markers (such as p53, p16, LaminB1, etc.) were detected by Western blotting.
[0025] The characteristics of cell senescence were detected by β-galactosidase staining.
[0026] 2.4 Cell function assessment: Western blotting was used to evaluate the effect of hyperoside on the polar distribution of AQP4 in astrocyte end feet.
[0027] 3. Data Analysis ImageJ was used to calculate the fluorescence positive area, fluorescence intensity, and gray value of the band, and GraphPadPrism 8.0 was used for data statistics. Unpaired T test, one-way ANOVA combined with post hoc Tukey test were used to analyze the experimental data according to the treatment factors. The data are expressed as mean ± standard error, and *p < 0.05 is considered statistically significant. The differences between the groups were compared to determine the protective effect of hyperoside on astrocyte aging.
[0028] IV. Experimental Results According to previous research, in order to verify the pharmacological effect of hyperoside in delaying astrocyte aging, the present invention first established an in vitro aging astrocyte model (such as Figure 1A Flow cytometry was used to detect the senescence markers of astrocytes (labeled by ACSA-2) cultured for 12 and 45 days. 12FDG labeling (such as Figure 1B As shown in Figure 2), firstly, the purity of the cultured primary astrocytes was above 81% (as shown in Figure 2). Figure 1C Second, compared with 12-day culture, C 12 FDG + ACSA-2 + The proportion of senescent astrocytes increased significantly (e.g. Figure 1D The results show that the astrocytes cultured for 12 days and 45 days were senescent astrocytes. Immunofluorescence was used to detect the co-labeling of the senescence marker p16 and the astrocyte marker GFAP in astrocytes cultured for 12 days and 45 days (as shown in Figure 2A). Figure 1E The results showed that p16 expression in astrocytes increased significantly at 45 days (as shown in Figure 1F Similarly, Western blotting data showed that the expression levels of senescence-related markers such as p16 and p53 in astrocytes at 45 days were significantly increased, while the expression level of Lamin B1 in astrocytes at 45 days was significantly decreased (as shown in Figure 1G , 1H As shown in Figure 2 ). Therefore, it was confirmed that the primary astrocytes cultured for 45 days were a model of senescent astrocytes.
[0029] The cell viability of senescent astrocytes cultured in vitro was detected after being stimulated with different concentrations of hyperoside for 48h and 72h. The results of CCK8 experiments showed that treatment of senescent astrocytes with hyperoside at concentrations of 0.1, 1 and 10 μM for 48h and 72h had no significant effect on cell viability (e.g. Figure 2A , 2B ), therefore, the subsequent experiments chose to use a longer treatment time of 72 h. After treating senescent astrocytes with 0.1, 1, and 10 μM hyperoside for 72 h, Western blotting was used to detect senescence-related indicators (as shown in Figure 3A As shown in Figure 2), the data showed that hyperoside significantly reduced p16 levels and increased Lamin B1 levels, suggesting that it alleviated the aging of astrocytes. In addition, hyperoside is also an AQP4 agonist, which may further promote the functional recovery of astrocytes by improving the water and ion balance of astrocytes (such as Figure 3B In summary, the concentration of hyperoside was 10 μM and the treatment condition of 72 h was selected for treating senescent astrocytes.
[0030] After aging astrocytes were further treated with 10 μM hyperoside for 72 h, AQP4 and aging-related indicators (such as Figure 4AAs shown in the figure), the data showed that hyperoside significantly increased the M23 subtype, enhanced the polarity of AQP4, and reduced the p16 level and increased the Lamin B1 level. It has been reported previously that Cyanamide can significantly stimulate the expression of AQP4, but has little effect on the polarity distribution of AQP4. Therefore, we chose to use 10μM concentration of Cyanamide as the positive reference of AQP4 agonist. Western blotting data showed that compared with Cyanamide, hyperoside significantly enhanced the polarity of AQP4, reduced the p16 level, and increased the Lamin B1 level, suggesting that it alleviated the aging of astrocytes, and the effect was better than Cyanamide (as shown in the figure). Figure 4B Second, the results of β-gal staining showed that after hyperoside treatment of senescent astrocytes, their β-gal + GFAP + The number of senescent astrocytes was significantly reduced, suggesting that the senescence of astrocytes was alleviated (e.g. Figure 4C as shown).
[0031] 5. Notes 5.1 Ensure the repeatability of the experiment and set the sample size appropriately.
[0032] 5.2 Pay attention to the solubility and stability of hyperoside and avoid the effects of light and high temperature.
[0033] Through the above experimental protocol, the effect of hyperoside on astrocyte senescence can be systematically evaluated.
Claims
1. Application of hyperoside in the preparation of drugs for preventing and treating brain aging.
2. The use according to claim 1, characterized in that: The drug dosage form for preventing and treating brain aging is capsule, tablet, oral preparation, microcapsule preparation, injection, suppository, spray or ointment.
3. The use according to any one of claims 1-2, characterized in that: The brain aging drug is used to treat patients suffering from brain aging diseases.
Citation Information
Patent Citations
Application of hyperin in preparation of medicament for treating climacteric syndrome and senile dementia
CN101757011A
Application of hyperin in preparing anti-ovarian-senescence drug
CN103070879A
Application of rhoifolin-hyperin composition in preparing medicine for treating and / or preventing neurodegenerative diseases
CN107648246A
Application of compound to treatment of senile dementia through protein accumulation reduction
CN108743599A
Application of hyperoside and cerebral ischemia-reperfusion injury treatment medicine
CN113952352A
